Engineering Versatile Bacteria-Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy

Overview

Journal Adv Sci (Weinh)

Specialty Biomedical Engineering

Date 2024 Jul 2

PMID 38952055

Authors

Ziheng Luo

Xiang Cheng

Bin Feng

Duoyang Fan

Xiaohui Liu

Ruyan Xie

Ting Luo

Seraphine V Wegner

Dayou Ma

Fei Chen

Wenbin Zeng

Affiliations

Soon will be listed here.

Abstract

In recent years, cancer immunotherapy has undergone a transformative shift toward personalized and targeted therapeutic strategies. Bacteria-derived outer membrane vesicles (OMVs) have emerged as a promising and adaptable platform for cancer immunotherapy due to their unique properties, including natural immunogenicity and the ability to be engineered for specific therapeutic purposes. In this review, a comprehensive overview is provided of state-of-the-art techniques and methodologies employed in the engineering of versatile OMVs for cancer immunotherapy. Beginning by exploring the biogenesis and composition of OMVs, unveiling their intrinsic immunogenic properties for therapeutic appeal. Subsequently, innovative approaches employed to engineer OMVs are delved into, ranging from the genetic engineering of parent bacteria to the incorporation of functional molecules. The importance of rational design strategies is highlighted to enhance the immunogenicity and specificity of OMVs, allowing tailoring for diverse cancer types. Furthermore, insights into clinical studies and potential challenges utilizing OMVs as cancer vaccines or adjuvants are also provided, offering a comprehensive assessment of the current landscape and future prospects. Overall, this review provides valuable insights for researchers involved in the rapidly evolving field of cancer immunotherapy, offering a roadmap for harnessing the full potential of OMVs as a versatile and adaptable platform for cancer treatment.

Citing Articles

Innovative Strategies in Oncology: Bacterial Membrane Vesicle-Based Drug Delivery Systems for Cancer Diagnosis and Therapy.

Li G, Pu S, You L, Gao Y, Zhong Y, Zhao H Pharmaceutics. 2025; 17(1).

PMID: 39861706 PMC: 11768367. DOI: 10.3390/pharmaceutics17010058.

Synthetic circRNA therapeutics: innovations, strategies, and future horizons.

Cai J, Qiu Z, Cho W, Liu Z, Chen S, Li H MedComm (2020). 2024; 5(11):e720.

PMID: 39525953 PMC: 11550093. DOI: 10.1002/mco2.720.

Engineering Versatile Bacteria-Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy.

Luo Z, Cheng X, Feng B, Fan D, Liu X, Xie R Adv Sci (Weinh). 2024; 11(33):e2400049.

PMID: 38952055 PMC: 11434149. DOI: 10.1002/advs.202400049.

References

Martinez-Greene J, Hernandez-Ortega K, Quiroz-Baez R, Resendis-Antonio O, Pichardo-Casas I, Sinclair D . Quantitative proteomic analysis of extracellular vesicle subgroups isolated by an optimized method combining polymer-based precipitation and size exclusion chromatography. J Extracell Vesicles. 2021; 10(6):e12087. PMC: 8077108. DOI: 10.1002/jev2.12087. View

Holmgaard R, Zamarin D, Li Y, Gasmi B, Munn D, Allison J . Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015; 13(2):412-24. PMC: 5013825. DOI: 10.1016/j.celrep.2015.08.077. View

Bishop D, WORK E . An extracellular glycolipid produced by Escherichia coli grown under lysine-limiting conditions. Biochem J. 1965; 96(2):567-76. PMC: 1207076. DOI: 10.1042/bj0960567. View

Marion C, Lee J, Sharma L, Park K, Lee C, Liu W . Toll-Like Receptors 2 and 4 Modulate Pulmonary Inflammation and Host Factors Mediated by Outer Membrane Vesicles Derived from Acinetobacter baumannii. Infect Immun. 2019; 87(9). PMC: 6704609. DOI: 10.1128/IAI.00243-19. View

Sies H, Jones D . Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020; 21(7):363-383. DOI: 10.1038/s41580-020-0230-3. View

Jin M, Jin W . The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020; 5(1):166. PMC: 7447642. DOI: 10.1038/s41392-020-00280-x. View

Fang R, Kroll A, Zhang L . Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. Small. 2015; 11(41):5483-96. PMC: 4641138. DOI: 10.1002/smll.201501284. View

Zhuang W, Wang Y, Nie W, Lei Y, Liang C, He J . Bacterial outer membrane vesicle based versatile nanosystem boosts the efferocytosis blockade triggered tumor-specific immunity. Nat Commun. 2023; 14(1):1675. PMC: 10039929. DOI: 10.1038/s41467-023-37369-0. View

Wirbel J, Pyl P, Kartal E, Zych K, Kashani A, Milanese A . Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med. 2019; 25(4):679-689. PMC: 7984229. DOI: 10.1038/s41591-019-0406-6. View

10.

Pan J, Li X, Shao B, Xu F, Huang X, Guo X . Self-Blockade of PD-L1 with Bacteria-Derived Outer-Membrane Vesicle for Enhanced Cancer Immunotherapy. Adv Mater. 2021; 34(7):e2106307. DOI: 10.1002/adma.202106307. View

11.

Tang L, Yin Y, Cao Y, Fu C, Liu H, Feng J . Extracellular Vesicles-Derived Hybrid Nanoplatforms for Amplified CD47 Blockade-Based Cancer Immunotherapy. Adv Mater. 2023; 35(35):e2303835. DOI: 10.1002/adma.202303835. View

12.

Fang J, Nakamura H, Maeda H . The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2010; 63(3):136-51. DOI: 10.1016/j.addr.2010.04.009. View

13.

Schaar V, de Vries S, Perez Vidakovics M, Bootsma H, Larsson L, Hermans P . Multicomponent Moraxella catarrhalis outer membrane vesicles induce an inflammatory response and are internalized by human epithelial cells. Cell Microbiol. 2010; 13(3):432-49. DOI: 10.1111/j.1462-5822.2010.01546.x. View

14.

Vivier E, Raulet D, Moretta A, Caligiuri M, Zitvogel L, Lanier L . Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013):44-9. PMC: 3089969. DOI: 10.1126/science.1198687. View

15.

Li Y, Zhao R, Cheng K, Zhang K, Wang Y, Zhang Y . Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy Immune Activation and Checkpoint Inhibition. ACS Nano. 2020; 14(12):16698-16711. DOI: 10.1021/acsnano.0c03776. View

16.

Gao J, Su Y, Wang Z . Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer. Adv Drug Deliv Rev. 2022; 186:114340. PMC: 9899072. DOI: 10.1016/j.addr.2022.114340. View

17.

Saxena M, van der Burg S, Melief C, Bhardwaj N . Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6):360-378. DOI: 10.1038/s41568-021-00346-0. View

18.

Tanaka T, Narazaki M, Kishimoto T . Interleukin (IL-6) Immunotherapy. Cold Spring Harb Perspect Biol. 2017; 10(8). PMC: 6071487. DOI: 10.1101/cshperspect.a028456. View

19.

van Weverwijk A, de Visser K . Mechanisms driving the immunoregulatory function of cancer cells. Nat Rev Cancer. 2023; 23(4):193-215. DOI: 10.1038/s41568-022-00544-4. View

20.

Luo Z, Cheng X, Feng B, Fan D, Liu X, Xie R . Engineering Versatile Bacteria-Derived Outer Membrane Vesicles: An Adaptable Platform for Advancing Cancer Immunotherapy. Adv Sci (Weinh). 2024; 11(33):e2400049. PMC: 11434149. DOI: 10.1002/advs.202400049. View